Skip to Main content Skip to Navigation
Journal articles

Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins

Abstract : Targeted genome editing has a great therapeutic potential to treat disorders that require protein replacement therapy. To develop a platform independent of specific patient mutations, therapeutic transgenes can be inserted in a safe and highly transcribed locus to maximize protein expression. Here, we describe an ex vivo editing approach to achieve efficient gene targeting in human hematopoietic stem/progenitor cells (HSPCs) and robust expression of clinically relevant proteins by the erythroid lineage. Using CRISPR-Cas9, we integrate different transgenes under the transcriptional control of the endogenous α-globin promoter, recapitulating its high and erythroid-specific expression. Erythroblasts derived from targeted HSPCs secrete different therapeutic proteins, which retain enzymatic activity and cross-correct patients' cells. Moreover, modified HSPCs maintain long-term repopulation and multilineage differentiation potential in transplanted mice. Overall, we establish a safe and versatile CRISPR-Cas9-based HSPC platform for different therapeutic applications, including hemophilia and inherited metabolic disorders.
Complete list of metadata

Cited literature [74 references]  Display  Hide  Download
Contributor : Myriam Bodescot Connect in order to contact the contributor
Submitted on : Wednesday, September 23, 2020 - 3:04:14 PM
Last modification on : Tuesday, January 4, 2022 - 5:55:28 AM
Long-term archiving on: : Thursday, December 3, 2020 - 4:08:06 PM


Publication funded by an institution



Giulia Pavani, Marine Laurent, Anna Fabiano, Erika Cantelli, Aboud Sakkal, et al.. Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins. Nature Communications, Nature Publishing Group, 2020, 11 (1), pp.3778. ⟨10.1038/s41467-020-17552-3⟩. ⟨inserm-02946890⟩



Les métriques sont temporairement indisponibles